1 completed, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow AVE 5026: new trials by email Literature Review of AVE 5026 trials Research Report on AVE 5026
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line Semuloparin sodium - Thrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL) | Phase 2 | Terminated | Sanofi | 2 | 2012-05-01 | 2016-05-03 |
| Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery Semuloparin sodium, Placebo (for Enoxaparin sodium), Enoxaparin sodium - Venous Thromboembolism | Phase 2 | Completed | Sanofi | 705 | 2006-05-01 | 2013-01-15 |
Thrombosis (1) · Venous Thromboembolism (1) · Venous Thrombosis (1)
Sanofi (2)
Argentina (1) · Bulgaria (1) · Chile (1) · Colombia (1) · Denmark (1) · Finland (1) · Greece (1) · Hungary (1) · Malaysia (1) · Mexico (1) · Norway (1) · Philippines (1) · Poland (1) · Portugal (1) · Romania (1)
2005 (1)